title: Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
abstract: Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as "poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10(6) CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10(6) CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10(6)/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.
authors.affiliation: Division of Hematology, Department of Oncohematology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. luca.arcaini@unipv.it
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.forename: Daniele
authors.initials: D
authors.lastname: Laszlo
authors.forename: Silvia
authors.initials: S
authors.lastname: Rizzi
authors.forename: Monica
authors.initials: M
authors.lastname: Balzarotti
authors.forename: Francesca
authors.initials: F
authors.lastname: Antoniazzi
authors.forename: Vittorio Ruggero
authors.initials: VR
authors.lastname: Zilioli
authors.forename: Elena
authors.initials: E
authors.lastname: Guggiari
authors.forename: Lucia
authors.initials: L
authors.lastname: Farina
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Todisco
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bonfichi
authors.forename: Sara Miqueleiz
authors.initials: SM
authors.lastname: Alamos
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001596:Benzylamines; D003131:Combined Modality Therapy; D057176:Compassionate Use Trials; D000080027:Cyclams; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor